UTAA06 / PersonGen Biomedicine - LARVOL DELTA

A phase I, open-label study of the novel B7-H3 targeted CAR-Vδ1T in patients with advanced solid tumours (ESMO 2025) - P1 | "Conclusions UTAA06, a first-in-class B7-H3-targeted CAR-Vδ1T therapy, demonstrates manageable safety and preliminary antitumor activity in heavily pretreated advanced solid tumor patients at doses up to 1×10ˆ9 cells. Ongoing evaluation will further characterize safety, pharmacokinetics, and efficacy in expanded cohorts."

Clinical • IO biomarker • Metastases • Oncology • Solid Tumor

UTAA06 Injection for Treatment of Advanced Malignant Solid Tumors (clinicaltrials.gov) - P1 | N=10 | Completed | Sponsor: Peking University | Recruiting ➔ Completed

Trial completion • Solid Tumor

A B7-H3-CAR-modified Vδ1 T cells showed potentanti-solid tumor potential (AACR 2024) - "UTAA06 exhibited extraordinary anticancer properties both in vitro and in vivo against solid tumors. Additionally, the outstanding manufacturing process of UTAA06 will facilitate the clinical application of this product."

IO biomarker • CNS Tumor • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Neuroblastoma • Oncology • Pancreatic Cancer • Solid Tumor • CD27 • CD276 • CXCR3 • CXCR6 • IL17A • IL2 • LAG3 • NKG2D • TNFRSF9

UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd.

New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • CD276

Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - P1 | N=10 | Recruiting | Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd.

New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • CD276